

Jackson K Mukonzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2669106/publications.pdf>

Version: 2024-02-01

33
papers

703
citations

623188

14
h-index

552369

26
g-index

36
all docs

36
docs citations

36
times ranked

1172
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperazine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0264339.	1.1	23
2	Application of the anatomical chemical system/defined daily doses: Challenges and way forward for resource-limited countries. Journal of Clinical Pharmacy and Therapeutics, 2021, , .	0.7	0
3	Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. Journal of Personalized Medicine, 2021, 11, 1303.	1.1	6
4	Medicinal plants used by traditional medicine practitioners to boost the immune system in people living with HIV/AIDS in Uganda. European Journal of Integrative Medicine, 2020, 35, 101011.	0.8	32
5	Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 107-114.	0.7	12
6	Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting. Malaria Journal, 2020, 19, 389.	0.8	2
7	Antiretroviral drugs found in pork on Ugandan market: Implications for HIV/AIDS treatment. One Health, 2020, 9, 100125.	1.5	2
8	Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity. Journal of Clinical Pharmacology, 2020, 60, 711-721.	1.0	1
9	Data on medicinal plants used by herbalists for boosting immunity in people living with HIV/AIDS in Uganda. Data in Brief, 2020, 29, 105097.	0.5	9
10	Healthcare professionals' perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda. Malaria Journal, 2020, 19, 63.	0.8	2
11	Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study. Pathogens, 2019, 8, 161.	1.2	4
12	Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. International Journal of Infectious Diseases, 2019, 83, 98-101.	1.5	20
13	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. Clinical Infectious Diseases, 2018, 67, 785-790.	2.9	25
14	A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients. BMC Medical Informatics and Decision Making, 2018, 18, 77.	1.5	35
15	Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials. HIV/AIDS - Research and Palliative Care, 2018, Volume 10, 151-155.	0.4	0
16	Transition modeling of neuropsychiatric impairment in HIV. Computers in Biology and Medicine, 2016, 73, 141-146.	3.9	3
17	CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics, 2016, 17, 603-613.	0.6	15
18	Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women. Drugs in R and D, 2015, 15, 351-362.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1229-1235.	1.0	8
20	Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes. <i>PLoS ONE</i> , 2014, 9, e86919.	1.1	61
21	CIHR canadian HIV trials network HIV workshop: ethical research through community participation and strengthening scientific validity. <i>Pan African Medical Journal</i> , 2014, 19, 44.	0.3	3
22	CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. <i>Pharmacogenomics</i> , 2014, 15, 1423-1435.	0.6	17
23	Characterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti tuberculosis therapy. <i>In Silico Pharmacology</i> , 2014, 2, 3.	1.8	16
24	The challenge of paediatric efavirenz dosing. <i>Aids</i> , 2014, 28, 1855-1857.	1.0	6
25	Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 261.	1.3	79
26	Over-the-counter suboptimal dispensing of antibiotics in Uganda. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 303.	1.1	58
27	Tips for charting the course of a successful health research career. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 163.	1.1	14
28	Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans. <i>HIV/AIDS - Research and Palliative Care</i> , 2013, 5, 309.	0.4	9
29	HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2011, 50, 531-540.	1.6	29
30	In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 536-543.	1.1	44
31	Genetic Variations in ABCB1 and CYP3A5 as well as Sex Influence Quinine Disposition Among Ugandans. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 346-352.	1.0	20
32	A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 690-699.	1.1	124
33	Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination. <i>Malaria Journal</i> , 2009, 8, 52.	0.8	12